Remove Medical Remove Pharmaceutical Remove Safety
article thumbnail

Medical Grade Skincare vs. Over-the-Counter Products: What’s the Difference?

Kim Gallo Esthetics

Are you wondering what the difference is between medical-grade skincare products and over-the-counter products? In this blog post, we will discuss the key differences between medical-grade skincare and over-the-counter products - so you can decide which route is best for you. What is medical-grade skincare?

article thumbnail

Oh, The Places Dermatology Will Go in 2024!

The Dermatology Digest

In 2023, dermatologists and their patients welcomed new drugs for acne, psoriasis, alopecia areata, and more, and 2024 promises to deliver real-world data on these medications along with even more therapeutic innovations across the spectrum of cutaneous diseases. We will, for sure, have new medications for chronic urticaria.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Warts and All: Verrica and Torii Team Up to Fund Global Phase 3 Trial of YCANTH for Common Warts

The Dermatology Digest

Verrica Pharmaceuticals Inc. has entered into an amendment to its existing licensing agreement with Torii Pharmaceutical Co. FDA and Japan’s Pharmaceuticals and Medical Device Agency (PMDA) on the proposed design of the Phase 3 clinical trial. With a prevalence of approximately 22 million patients in the U.S.

article thumbnail

Retinol Serum: Is It Safe for Kids and Teens?

First Derm

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 104
article thumbnail

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Hit Higher Treatment Targets

The Dermatology Digest

These findings indicate that upadacitinib may address an unmet medical need in patients with moderate-to-severe AD who do not achieve an adequate response while taking dupilumab,” conclude researchers who were led by Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University in New Haven, CT.

article thumbnail

Topline Results: Verrica’s VP-315 Performs Well in BCC Trial

The Dermatology Digest

Verrica Pharmaceuticals Inc.’s The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma.

Safety 36
article thumbnail

Lumbrokinase – An Enzyme for More Than Just Heart Health: Martin Kwok

Aesthetics Advisor

Currently there are three main categories of pharmaceutical agents used to treat or prevent ischemia issues: thrombolytics, antiplatelets, and anticoagulants. Is there not a safer and also effective natural option for helping patients besides the above categories of pharmaceuticals? In a paper published in 2007, Zhao et al.